HLA Typing for Celiac Disease
Use
HLA Typing for Celiac Disease is used to identify genetic markers—specifically HLA‑DQ2 (DQA1*05/DQB1*02) and HLA‑DQ8 (DQA1*03/DQB1*0302), including HLA‑DQA1* and HLA‑DQB1* alleles—that are associated with increased susceptibility to celiac disease. The presence of these HLA‑DQ haplotypes may help assess genetic risk and potentially rule out celiac disease in appropriate clinical contexts.
Special Instructions
Insurance authorization is required prior to draw for outpatients; testing is available daily. It is acceptable to send inpatient samples without prior authorization. Collection may be performed in sodium heparin (green‑top), EDTA (pink‑top or royal blue‑top), or sodium citrate (light blue‑top) tubes.
Limitations
Technical limitations include that the test may be 'Unacceptable' if received frozen or if the sample is clotted. Genetic susceptibility markers do not confirm diagnosis of disease—they only inform risk. Interpretation may be equivocal in certain haplotypes, and a negative result does not entirely exclude risk; also not diagnostic of active celiac disease but provides genetic risk context.
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
6 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3‑5 mL
Minimum Volume
3 mL
Container
Lavender (EDTA) tube; sodium heparin (green‑top); EDTA pink‑top; EDTA royal blue‑top; sodium citrate light blue‑top
Storage Instructions
Ambient or refrigerated
Causes for Rejection
Received frozen; Clotted
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 Days |
| Refrigerated | 7 Days |
| Frozen | Unacceptable |